Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CAPR
CUSIPN/A
Phone310-358-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio9.94
Quick Ratio9.94
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.67 million
Price / Sales15.48
Cash FlowN/A
Price / CashN/A
Book Value$0.44 per share
Price / Book3.23
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$2.43 million
Net Margins110.98%
Return on Equity-485.43%
Return on Assets-85.83%
Miscellaneous
Employees40
Outstanding Shares29,110,000
Market Cap$43.37
Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics Inc (NASDAQ:CAPR) issued its quarterly earnings results on Thursday, May, 10th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.03. The biotechnology company had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.49 million. Capricor Therapeutics had a negative return on equity of 485.43% and a net margin of 110.98%. View Capricor Therapeutics' Earnings History.
When is Capricor Therapeutics' next earnings date?
What price target have analysts set for CAPR?
3 Wall Street analysts have issued 12 month price objectives for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $9.00. On average, they expect Capricor Therapeutics' stock price to reach $6.05 in the next twelve months. This suggests a possible upside of 326.1% from the stock's current price. View Analyst Ratings for Capricor Therapeutics.
What is the consensus analysts' recommendation for Capricor Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include BioDelivery Sciences International (BDSI), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Calithera Biosciences (CALA), Acer Therapeutics (ACER), Bellerophon Therapeutics (BLPH), Spring Bank Pharmaceuticals (SBPH), Newron Pharmaceuticals (NWPHF), AcelRx Pharmaceuticals (ACRX), Fortress Biotech (FBIO), Eleven Biotherapeutics (EBIO), MEI Pharma (MEIP), Protagonist Therapeutics (PTGX), Chembio Diagnostics (CEMI) and XBiotech (XBIT).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
- Joshua A. Kazam, Director (Age 40)
Has Capricor Therapeutics been receiving favorable news coverage?
News articles about CAPR stock have trended positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capricor Therapeutics earned a coverage optimism score of 0.28 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.15 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Capricor Therapeutics?
Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of CAPR stock can currently be purchased for approximately $1.42.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $43.37 million and generates $2.67 million in revenue each year. The biotechnology company earns $2.43 million in net income (profit) each year or ($0.44) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ CAPR)
MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe CAPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CAPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
